What X-Therma does

X-Therma is a privately held biotechnology company founded in 2014 and headquartered in Hercules, California (with R&D operations in Richmond, CA and a European subsidiary in Innsbruck, Austria). The company develops a proprietary biopreservation platform built on synthetic biomimetic peptoids — molecules that emulate the ice-inhibiting function of natural antifreeze proteins found in arctic species. This chemistry enables ice-free, non-toxic preservation of cells, tissues, organs, and engineered biologics across a temperature spectrum from -5°C to -196°C, addressing limitations of conventional cryopreservation methods that rely on toxic dimethyl sulfoxide (DMSO) and serum-containing formulations.

X-Therma commercializes four integrated product lines. XT-Thrive is a cGMP-grade, DMSO-free, chemically defined cryopreservation media for cell and tissue preservation at ultra-low temperatures; it received FDA Drug Master File acceptance in January 2024 and achieved GMP commercial readiness in May 2024. XT-ViVo is a non-toxic organ preservation solution that, paired with the TimeSeal smart transport device (a portable, sensor-enabled transporter requiring no external power, perfusion, oxygen, or blood), received FDA Breakthrough Device Designation in 2022 for human kidney preservation up to 120 hours. XT-NoVo is the most recently launched (June 2025) ice-free, sub-zero preservation platform operating at -5°C for up to five days, targeting biologics and cell therapy logistics. The company has demonstrated the world's first transatlantic subzero organ transport, with five successful pig kidney transports between Baltimore and Innsbruck and 200-day post-transplant survival.

X-Therma operates a direct enterprise sales model targeting biopharmaceutical companies, cell and gene therapy manufacturers, organ transplant programs, biobanks, and advanced tissue engineering firms. Pricing is quote-based with no publicly disclosed list pricing. The company has validated its platform with more than 60 global biotech and biopharma partners and maintains strategic research collaborations with Johns Hopkins University School of Medicine, Medical University of Innsbruck, Vitalant Research Institute, AlloSource, and Theradaptive. To date, X-Therma has raised approximately $35.4 million in combined equity and non-dilutive funding (a $13 million Series A led by LOREA AG in December 2021 and a $22.4 million oversubscribed Series B co-led by Starling Locke Capital and LOREA AG in March 2024), in addition to over $11 million in cumulative grants from the NSF, U.S. Department of Defense, and California Institute for Regenerative Medicine.

Name

X-Therma

Legal name

X-Therma Inc.

Website

https://x-therma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

X-Therma is a venture-backed biotechnology company that develops a proprietary biomimetic peptoid-based biopreservation platform enabling DMSO-free, ice-free preservation of cells, tissues, organs, and biologics for regenerative medicine, serving cell therapy manufacturers, transplant programs, and biobanks globally.

Ownership category

akta.pro rank

Product category

Biopreservation / Cryopreservation Solutions

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)

akta.pro secondary industry

Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK)

Keywords

• Cryopreservation media
• Biopreservation solutions
• Organ preservation technology
• Cell therapy preservation
• Regenerative medicine cold chain

Headquarters

HQ city

Richmond

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. XT-Thrive Product Sales: Sale of cGMP-grade DMSO-free cryopreservation media for cell and tissue preservation. XT-Thrive is sold directly to biopharma companies, biotech manufacturers, and research institutions for use in cell therapy manufacturing, gene therapy production, and tissue banking applications.
2. XT-ViVo & TimeSeal Organ Preservation Systems: Sale of organ preservation solutions and smart transport devices for transplantation applications. Revenue from direct sales to transplant programs, organ procurement organizations, and healthcare institutions. FDA Breakthrough Device Designation supports commercial pathway.
3. XT-NoVo Biopreservation Platform: Commercial launch of sub-zero preservation platform for cell therapy logistics. Revenue from product sales to regenerative medicine companies requiring extended cold chain storage and transport capabilities.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

X-Therma develops and manufactures a proprietary biopreservation platform based on biomimetic antifreeze peptoids that enable ice-free, non-toxic, DMSO-free preservation of cells, tissues, and organs at sub-zero temperatures. The company sells cGMP-grade cryopreservation media (XT-Thrive), organ preservation solution (XT-ViVo), and smart transport hardware (TimeSeal) to biopharmaceutical companies, cell and gene therapy manufacturers, transplant programs, and research institutions. The platform extends organ preservation from hours to multiple days and cell therapy shelf life from 1-2 days to up to five days.

Product overview

X-Therma offers a biopreservation platform with three integrated product lines addressing different preservation needs. XT-Thrive® is the foundational cGMP-grade cryopreservation media for cells and tissues at ultra-low temperatures (-70°C to -196°C). XT-ViVo® & TimeSeal® form an integrated organ preservation and transport system with FDA Breakthrough Device Designation for multi-day kidney preservation up to 120 hours. XT-NoVo® & TimeSeal® represents the latest generation platform for ice-free, sub-zero preservation of biologics and cell therapies at -5°C for up to five days. All products are built on proprietary peptoid technology inspired by natural antifreeze proteins, enabling non-toxic, DMSO-free preservation across the regenerative medicine cold chain.

Differentiator

Problem solved

Functional benefit

Brands

• XT-Thrive: DMSO-free, chemically defined, cGMP grade cryopreservation solution for cell and tissue cryopreservation at ultra-low temperatures (-70°C to -196°C)
• XT-ViVo
• XT-NoVo
• TimeSeal

Products and services

• XT-Thrive DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media for preservation of mammalian cells and tissues at ultra-low temperatures (-70°C to -196°C). Incorporates peptoid-based cryoprotectants inspired by natural antifreeze proteins to prevent aberrant ice formation and shock-induced ice damage. cGMP grade with FDA-accepted Drug Master File (DMF). Designed for cell and gene therapy manufacturers, biopharma companies, and biobanking operations as a plug-and-play alternative to DMSO- and serum-containing legacy cryopreservation solutions.
• XT-ViVo Non-toxic, serum- and protein-free organ preservation solution using synthetic biomimetics of antifreeze proteins. Prevents ice crystal formation during storage at subzero temperatures (0°C to -20°C) while supporting reduced metabolism and ischemic damage reduction. FDA Breakthrough Device Designation for kidney preservation up to 120 hours. Designed for transplant centers, organ procurement organizations, and transplant programs as a multi-day preservation solution.
• TimeSeal Smart, portable, easy-to-use organ and biologics transporter with integrated intelligent sensor system providing precise temperature tracking and real-time monitoring during transport. Operates without requiring external power, perfusion, oxygen, or blood. Configurable for static and box configurations. Enables subzero organ transport for multi-day preservation and pairs with XT-ViVo and XT-NoVo solutions.
• XT-NoVo Ice-free, DMSO-free, chemically defined sub-zero biopreservation solution using synthetic biomimetic antifreeze peptoids to prevent ice formation at -5°C. Preserves cells, tissues, organoids, and engineered products for up to five days while retaining structural and functional integrity. Paired with TimeSeal for end-to-end cold chain logistics for biologics and cell therapies. Validated with Theradaptive for 5,500-mile cross-country organoid shipping.

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Johns Hopkins University School of MedicinecoreStrategic or Co-development PartnerLong-standing research collaboration for organ preservation technology. Dr. Gerald Brandacher and team conducted world's first subzero transatlantic organ transports. NIH SBIR Direct-to-Phase II program supported research. Collaboration validated across multiple successful pig kidney transplant studies.
• Medical University of InnsbruckcoreStrategic or Co-development PartnerEuropean research partner for subzero organ preservation studies. Surgical and research team assessed transported pig kidneys on clinical-grade perfusion devices. Partner in transatlantic transport demonstrations between Baltimore and Austria.
• Lawrence Berkeley National LaboratorysupportingStrategic or Co-development PartnerSelected as Industrial User at Lawrence Berkeley National Laboratory, providing access to research infrastructure and capabilities for technology development.
• AlloSourcesupportingStrategic or Co-development PartnerPartner on NSF Phase IIB funding for tissue preservation product development. AlloSource Innovation Center collaboration to advance on-demand tissue availability for patients.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• TransMedics: Public company developing the Organ Care System (OCS) for warm perfusion and transport of donor organs (heart, lung, liver). Direct competitor to X-Therma's XT-ViVo/TimeSeal platform in the organ preservation and transplantation market.
• Paragonix Technologies: Private company developing FDA-cleared organ preservation and transport devices (SherpaPak for kidneys, LUNGguard for lungs). Directly competes with X-Therma's TimeSeal organ transporter in the same clinical use cases.
• OrganOx: Private UK-based company developing the metra normothermic liver preservation device. Competes with X-Therma in organ preservation technology, with potential future expansion into other organs similar to X-Therma's pipeline.
• BioLife Solutions: Public company (BLFS) supplying CryoStor and HypoThermosol cryopreservation media for cell and gene therapy manufacturers. Directly competes with X-Therma's XT-Thrive as a chemically-defined, GMP-grade preservation media product.
• Akron Bio: Private company providing cGMP-grade cryopreservation media, including DMSO-free formulations, for cell therapy manufacturers. Directly competes with X-Therma's XT-Thrive in the regenerative medicine supply chain.

Broad incumbents

• Sartorius: Large public life sciences company offering bioprocessing equipment, including cryopreservation and cold chain solutions for cell and gene therapy manufacturers. Competes broadly across X-Therma's customer base with a much wider product portfolio.
• Cytiva: Global life sciences company (Danaher subsidiary) providing bioprocessing and cell therapy manufacturing solutions, including cold chain management products. Broad incumbent serving many of the same cell therapy customers as X-Therma.
• STEMCELL Technologies: Private Canadian company offering cell culture media, cryopreservation reagents, and tissue storage solutions for research and clinical applications. Competes with X-Therma in cell banking and research-grade preservation media.

Emerging players

• TMRW Life Sciences: Private company providing automated cryopreservation and biobanking for IVF, reproductive cells, and high-value biologics. Adjacent competitor to X-Therma's XT-NoVo platform for sub-zero biologics preservation.
• Vineti: Private company providing cell therapy orchestration and cold chain logistics software platform. Adjacent to X-Therma's biologics logistics offering — addresses same pain points in cell therapy supply chain with a digital layer rather than chemistry solution.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/x_therma
• Facebookfacebook.com/xtherma
• LinkedInlinkedin.com/company/x-therma-inc-

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about X-Therma